News stories about Amgen (NASDAQ:AMGN) have trended positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amgen earned a media sentiment score of 0.28 on Accern’s scale. Accern also gave media headlines about the medical research company an impact score of 46.0678478845113 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the headlines that may have effected Accern’s analysis:

Shares of Amgen (NASDAQ AMGN) traded down 0.53% on Monday, reaching $186.47. 2,443,770 shares of the company’s stock traded hands. The firm has a market capitalization of $136.06 billion, a P/E ratio of 16.98 and a beta of 1.35. Amgen has a 52 week low of $133.64 and a 52 week high of $191.10. The company’s 50-day moving average is $175.65 and its 200-day moving average is $169.26.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the previous year, the company earned $2.84 earnings per share. Amgen’s revenue for the quarter was up 2.1% on a year-over-year basis. Equities research analysts anticipate that Amgen will post $12.57 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were paid a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.47%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s payout ratio is currently 41.93%.

A number of equities analysts recently issued reports on the company. UBS AG restated a “neutral” rating and issued a $175.00 target price (up previously from $174.00) on shares of Amgen in a research note on Tuesday, June 13th. Morgan Stanley raised their target price on Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, June 13th. BMO Capital Markets restated a “buy” rating and set a $198.00 target price (down from $200.00) on shares of Amgen in a research report on Monday, May 22nd. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $203.00 target price (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. Finally, Royal Bank Of Canada started coverage on Amgen in a research report on Thursday. They set a “sector perform” rating and a $192.00 target price on the stock. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $186.14.

ILLEGAL ACTIVITY WARNING: This story was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Insider Buying and Selling by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with's FREE daily email newsletter.